Evidence map›Paper›PMID 41902989›Full record

ReviewMetabolic brain disease2026

Animal models of multiple sclerosis: applications and future directions in disease research.

Sujitha R, Shajahan K, Yogalakshmi R, Velan R N, Khiren S, Divya R, Monisha A

Abstract readReview
PubMed Publisher
In one paragraph

Review in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sujitha RFaculty of pharmacy, Dr. MGR Educational and Research Institute, Velappanchavadi, Chennai 77, India.ORCID 0009-0005-9099-4145
Shajahan KFaculty of pharmacy, Dr. MGR Educational and Research Institute, Velappanchavadi, Chennai 77, India.ORCID 0009-0006-9701-8742
Yogalakshmi RFaculty of pharmacy, Dr. MGR Educational and Research Institute, Velappanchavadi, Chennai 77, India.ORCID 0009-0002-7340-5618
Velan R NFaculty of pharmacy, Dr. MGR Educational and Research Institute, Velappanchavadi, Chennai 77, India.ORCID 0009-0004-2080-3617
Khiren SFaculty of pharmacy, Dr. MGR Educational and Research Institute, Velappanchavadi, Chennai 77, India.ORCID 0009-0007-9022-4583
Divya RFaculty of pharmacy, Dr. MGR Educational and Research Institute, Velappanchavadi, Chennai 77, India.ORCID 0000-0002-4431-2730
Monisha AFaculty of pharmacy, Dr. MGR Educational and Research Institute, Velappanchavadi, Chennai 77, India. monishaa.pharm@drmgrdu.ac.in.ORCID 0009-0006-5511-0161

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic, inflammatory, and demyelinating disorder of the central nervous system that affects nearly two million individuals worldwide. Characterized by axonal damage, neurodegeneration, and immune-mediated demyelination, MS remains without a cure, and its precise etiology is still unclear. Evidence strongly supports the role of autoimmune mechanisms, with both environmental factors and genetic contributing to disease onset and progression. Animal models have been indispensable in advancing our understanding of MS pathogenesis and in testing therapeutic strategies. Among these, experimental autoimmune encephalomyelitis is the most widely used, closely reproducing immune-mediated inflammation and demyelination. Viral models, such as Theiler's murine encephalomyelitis virus and Semliki Forest virus, provide insights into virus-induced demyelination, while toxin-induced models (e.g., cuprizone and lysolecithin) are valuable for studying demyelination and remyelination processes. Additionally, transgenic and knockout models allow the exploration of specific genetic contributions to disease mechanisms. Despite their limitations no single model fully recapitulates the heterogeneity of MS these approaches remain critical for unraveling disease mechanisms, identifying biomarkers, and developing novel therapeutic interventions. This review highlights the applications and limitations of existing animal models and discusses emerging directions in MS research.

Indexed as

Disease Models, AnimalEncephalomyelitis, Autoimmune, ExperimentalMultiple SclerosisAnimalsHumansBiomarkersExperimental autoimmune encephalomyelitisMultiple sclerosisToxin modelsViral models

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.